<DOC>
	<DOCNO>NCT02796209</DOCNO>
	<brief_summary>Atomoxetine , selective norepinephrine transporter ( NET ) blocker , increase stand blood pressure improve neurogenic orthostatic hypotension ( NOH ) -related symptom great extent midodrine , current standard care . Atomoxetine could new therapeutic alternative treatment NOH patient autonomic failure , particularly multiple system atrophy ( MSA ) . The propose study consist open-label , dose-optimization phase follow randomize , double-blind , placebo-controlled , 2x2 crossover phase .</brief_summary>
	<brief_title>Norepinephrine Transporter Blockade , Autonomic Failure</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Pure Autonomic Failure</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>Neurogenic Orthostatic Hypotension ( define reduction â‰¥30 mmHg drop SBP within 3 minute stand , associate impaired autonomic reflex assess autonomic function test . Pregnancy breastfeed Hypersensitivity atomoxetine ( severe allergic reaction , rash , urticaria , anaphylaxis ) Use norepinephrine transporter inhibitor Wellbutrin ( Bupropion ) , Cymbalta ( Duloxetine ) , Effexor ( venlafaxine ) , Pristiq ( desvenlafaxine ) , Savella ( milnacipran ) Previous history ( within 14 day prior enrollment ) current use monoamine oxidase inhibitor Concomitant use strong CYP2D6 inhibitor delavirdine , paroxetine , fluoxetine , quinidine Preexisting sustain severe hypertension ( BP 140/80 mmhg sit position ) Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 2 x upper limit normal range ) Impaired renal function ( serum creatinine equal 1.6 mg/dl ) Myocardial infarction within 6 month prior enrollment Congestive heart failure ( LV hypertrophy acceptable ) History serious neurologic disease cerebral hemorrhage , stroke Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study , mental condition render subject unable understand nature , scope , possible consequence study Patients narrow angle glaucoma Patients history pheochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>atomoxetine</keyword>
	<keyword>autonomic failure</keyword>
</DOC>